Genetic Predisposition to Cardiovascular Disease in Patients With Cancer

Figures

• 

  Figure 1. Genetic Predisposition to Cardiovascular Disease in Cancer: Implications and Potentials Genetic variants may render cancer patients more prone to cardiotoxicity from anticancer therapies; may further increase the susceptibility to cancer-related cardiovascular complications, such as thromboembolic complications; and may predispose to concomitant cancer and cardiovascular disease (CVD) development, as with clonal hematopoiesis of indeterminate potential mutations. Knowledge of the impact of the genetic background on the risk of cardiovascular disease may allow a more personalized approach to anticancer therapy based on cardiotoxicity risk, the identification of new targets for cardiotoxicity prevention, and further prevention strategies to prevent cancer-related cardiovascular complications strategies (eg, anticoagulation prophylaxis) and even to mitigate the risk of cardiovascular disease and cancer in the general population. See text for details.